根据肿瘤CD274(程序性细胞死亡1配体1)表达状态探讨阿司匹林使用与结直肠癌生存的关系
基于护士健康研究和卫生专业人员随访研究中617例直肠癌和结肠癌患者,分析诊断后阿司匹林使用与生存的关系按肿瘤CD274表达状态分层。诊断后阿司匹林使用与结直肠癌特异性生存的关联因CD274表达状态而异(交互作用P<.001);在CD274低表达患者中,规律使用阿司匹林者的多变量校正风险比为0.16(95%CI,0.06-0.41),而在CD274高表达患者中为1.01(95%CI,0.61-1.67)。结论认为阿司匹林使用与结直肠癌生存的关联在CD274低表达肿瘤患者中比CD274高表达肿瘤患者更强。
要点
- 诊断后阿司匹林使用与结直肠癌特异性生存的关联因肿瘤CD274表达状态而异(交互作用P<.001)。
- CD274低表达患者中,规律使用阿司匹林者的多变量校正HR为0.16(95%CI,0.06-0.41)。
- CD274高表达患者中,规律使用阿司匹林者的多变量校正HR为1.01(95%CI,0.61-1.67)。
核心结论
- 阿司匹林使用与结直肠癌生存的关联在CD274低表达肿瘤患者中比CD274高表达肿瘤患者更强。
- 研究结果提示阿司匹林的抗肿瘤效应可能因免疫检查点状态而异。
研究设计与样本
- 研究基于护士健康研究和卫生专业人员随访研究中617例直肠癌和结肠癌患者的数据。
- 采用免疫组织化学方法检测肿瘤CD274表达状态,分析诊断后阿司匹林使用与患者生存的关联。
- 使用多变量Cox比例风险回归模型控制潜在混杂因素,包括疾病分期、微卫星不稳定状态、CpG岛甲基化表型、长散在核苷酸元件-1甲基化、环氧合酶-2(PTGS2)和CDX2表达,以及KRAS、BRAF和PIK3CA突变。
主要发现
- 诊断后阿司匹林使用与结直肠癌特异性生存的关联因CD274表达状态而异(交互作用P<.001)。
- 与不使用阿司匹林者相比,规律使用阿司匹林者在CD274低表达患者中的多变量校正风险比为0.16(95%CI,0.06-0.41)。
- 与不使用阿司匹林者相比,规律使用阿司匹林者在CD274高表达患者中的多变量校正风险比为1.01(95%CI,0.61-1.67)。
- 这种差异关联在微卫星稳定或PIK3CA野生型疾病患者中,以及在PTGS2表达、CDX2表达、肿瘤浸润淋巴细胞或诊断前阿司匹林使用状态分层中似乎一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Blockade of the programmed cell death 1 (PDCD1, PD-1) immune checkpoint pathway can improve clinical outcomes in various malignancies. Evidence suggests that aspirin (a widely used nonsteroidal anti-inflammatory drug) not only prolongs colorectal cancer survival, but can also activate T cell-mediated antitumor immunity and synergize with immunotherapy through inhibition of prostaglandin E2 production. We hypothesized that the survival benefit associated with aspirin might be stronger in colorectal carcinoma with a lower CD274 (PDCD1 ligand 1, PD-L1) expression level that resulted in lower signaling of the immune checkpoint pathway. Patients and Methods Using data from 617 patients with rectal and colon cancer in the Nurses' Health Study and the Health Professionals Follow-Up Study, we examined the association of postdiagnosis aspirin use with patient survival in strata of tumor CD274 expression status measured by immunohistochemistry. We used multivariable Cox proportional hazards regression models to control for potential confounders, including disease stage, microsatellite instability status, CpG island methylator phenotype, long interspersed nucleotide element-1 methylation, cyclooxygenase-2 (PTGS2), and CDX2 expression, and KRAS, BRAF, and PIK3CA mutations. Results The association of postdiagnosis aspirin use with colorectal cancer-specific survival differed by CD274 expression status ( Pinteraction < .001); compared with aspirin nonusers; multivariable-adjusted hazard ratios for regular aspirin users were 0.16 (95% CI, 0.06 to 0.41) in patients with low CD274 and 1.01 (95% CI, 0.61 to 1.67) in patients with high CD274. This differential association seemed consistent in patients with microsatellite-stable or PIK3CA wild-type disease and in strata of PTGS2 expression, CDX2 expression, tumor-infiltrating lymphocytes, or prediagnosis aspirin use status. Conclusion The association of aspirin use with colorectal cancer survival is stronger in patients with CD274-low tumors than CD274-high tumors. Our findings suggest a differential antitumor effect of aspirin according to immune checkpoint status.
引用
- Hamada T, Cao Y, Qian ZR, et al. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. J Clin Oncol. 2017. PMID: 28406723. doi:10.1200/JCO.2016.70.7547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。